A mouse model of human ovarian cancer was used to investigate the effect of adenovirus-mediated thymidine kinase gene therapy (gt) in combination with chemotherapy. One hundred sixty female CD-1 nu/nu mice were injected intraperitoneally with Ov-ca-2774 cells. Onset of intraperitoneal treatment with either topotecan (6 or 12 mg/kg) or paclitaxel (18 or 36 mg/kg) was on day 4 or 8 and was repeated once after 4 days. Animals scheduled for gt received intraperitoneal application of adv/rsv-tk 1 day prior to chemotherapy and were subsequently treated with ganciclovir (gcv; 10 mg/kg, every 12 hours for 6 days). Survival was chosen as study endpoint. Whereas tumor burden had hardly any effect on survival, the lower dose of either cytotoxic agent was seen to be more effective than the higher one. In the topotecan group, an interaction between topotecan and gt was present. Survival was best for animals treated with low dose of topotecan only, the addition of gt reduced survival time significantly. With the higher dose, gt did not affect survival time. With paclitaxel, only slight effects of gt on the survival times were seen. Due to treatment toxicity, this animal model may be problematic for the evaluation of gt and chemotherapy combinations. The effect of dose varied strongly with time. Mice treated with high-dose chemotherapy had a substantially increased risk of dying in the time period following application, whereas this advantage of the lower dose disappeared later. Cancer Gene Therapy ( 2002 ) 9, 478 -481 DOI: 10.1038 / sj / cgt / 7700462 Keywords: ovarian cancer; gene therapy; chemotherapy; topotecan; paclitaxel A mouse model of human ovarian cancer was used to investigate the effect of adenovirus ( adv )-mediated thymidine kinase ( tk ) suicide gene therapy (gt ) in combination with chemotherapy utilizing either topotecan or paclitaxel. Our in vitro data suggested a synergism between topotecan, an inhibitor of topoisomerase I, and tkgt.
A mouse model of human ovarian cancer was used to investigate the effect of adenovirus ( adv )-mediated thymidine kinase ( tk ) suicide gene therapy (gt ) in combination with chemotherapy utilizing either topotecan or paclitaxel. Our in vitro data suggested a synergism between topotecan, an inhibitor of topoisomerase I, and tkgt. 1 In contrast, the combination of paclitaxel, which binds to tubulin thereby preventing the polymerization of microtubules, and tk -gt was not superior to each single -treatment modality in vitro. 1 To investigate this issue in vivo, female CD -1 nu/ nu mice were injected intraperitoneally with the human epithelial ovarian cancer cell line Ov -ca -2774 and treated with chemotherapy (topotecan or paclitaxel ) either alone or in combination with gt. Because Ov -ca -2774 cells are p53 mutated and have been found to be resistant to cisplatin, 2 neither cis -nor carboplatin were included.
Most interestingly, an increased toxicity of the combined treatment with topotecan and gt was observed whereas gt virtually did not influence the efficacy of chemotherapy with paclitaxel. Because of the unexpected increase in toxicity, the potential synergism between topotecan and gt could not be evaluated in this model.
Materials and methods
Maintenance of Ov -ca-2774 cells and construction of the recombinant adv carrying the herpes simplex virus (hsv )-derived tk gene under control of the rous sarcoma virus ( rsv ) promoter (adv /rsv -tk ) were described previously. 3 One preparation of adv/ rsv -tk containing 5.75Â10 11 normal adjusted standard infectious units (IU NAS ) /mL and 4.2Â10 12 particles / mL was used for the whole experiment. 4 Topotecan was obtained from SmithKline Beecham Pharmaceuticals ( Philadelphia, PA ) and paclitaxel was purchased from Bristol -Myers Pharmaceuticals (New York, NY ).
Animal model and experimental design
The study had the approval of the local biosafety subcommittee and animal research committee of Baylor College of Medicine (H#1665); the local animal research committee reports to the Institutional Animal Care and Use Committee. Ov -ca -2774 tumor cells resuspended in Hanks buffer ( 1Â10 8 cells per 2 mL ) were injected intraperitoneally into female CD -1 nu/nu mice (Charles River Laboratories, Wilmington, MA ) aged 6-10 weeks. Subsequently, mice were weighed twice daily. Immediately after tumor-induced death or, in case of long -time survivors, on sacrifice, cytological examination of ascites and histological examination of heart, lung, diaphragm, liver, spleen, kidney, intestine, uterus, ovary, and omentum were performed ( data not shown).
Onset of gt (6.67Â10 8 IU NAS ) in combination with intraperitoneal application of ganciclovir (gcv; 10 mg / kg, every 12 hours for 6 days ) was either on day 3 or 7. This viral dose is in the middle of the adv/ rsv -tk dose -response curve for the tumor burden chosen for this experiment and no long -term survival was ever observed under these conditions using this dose of gt alone ( see Ref. [1 ] and references cited therein ). Two doses of topotecan (6 and 12 mg /kg ) and paclitaxel ( 18 and 36 mg / kg) were selected from pilot animal experiments (personal communication, Dr R Johnson, SmithKline Beecham Pharmaceuticals ) and two cycles of chemotherapy with 4 days time interval were applied starting at days 4 and 8, respectively. With the lower doses of either topotecan or paclitaxel a reduction of tumor mass but not a complete remission could be achieved (personal communication ). Higher doses were also included to investigate, whether the efficacy of chemotherapy and of combined treatment could be improved. A prospective randomized treatment plan (16 treatment modalities and 10 mice per group ) was designed to evaluate the impact of combined versus single -modality therapy. Survival was defined as the study endpoint. Although 160 mice were included in the study, 8 animals were excluded from the evaluation due to incomplete documentation. In addition, treatment differed from the planned one in five cases, resulting in group sizes of either 11 or 9 instead of 10. However, as genetically identical mice were used for this study, it appears rather unlikely that this deviation from the treatment plan would have had an influence on the result and we decided to proceed with the analysis. Mice were grouped ''as treated'' rather than ''as randomized.''
Statistical methods
As the main purpose of this study was to evaluate the effect of gt combined with either paclitaxel or topotecan, animals of the subgroups defined by the agent of chemotherapy were analyzed separately. Within these two groups, a 2 3 design with the effects tumor burden at onset of therapy ( ''low vs. high''), dose of chemotherapy (''half vs. full'' ) and gt (''no vs. yes'') was chosen. This model enabled us to inves tigate if these three factors had an influence on survival, and whether an interaction between chemotherapy and gt occurred.
Survival time was calculated from the day of tumor inoculation to the day of death. Mice that were killed at the end of the observation period were treated as censored observations. Survival rates were calculated according to the method of Kaplan and Meier, P values from univariate investigations were based on the log -rank test. The Cox regression model was used to estimate the contribution of the different factors with the corresponding 95% confidence intervals.
As prespecified, the three main treatment effects were estimated separately in the two treatment-defined groups. In some cases, plots of the survival times indicated an effect varying with time. We used plots of log( À log( time ) ) versus log( time ) to check the proportional hazards assumption. Furthermore, we used three time intervals and tested the deviation of the effect in the second and third interval by a Wald test. Time intervals were included if a 1% significance level was reached. Intervals chosen were 0 -50, 51 -100 and more than 100 days for the topotecan group. Due to longer survival times of mice treated with paclitaxel, intervals of yInteraction between dose of topotecan and gt present; P value of test for interaction = .016.
zP value for test of time variation = .007.
Cancer Gene Therapy
Combination of tk-gene therapy with topotecan or paclitaxel DG Kieback et al 0 -60, 61-120 and more than 120 days were selected. Interactive effects of dose and gt were estimated and tested in the model with all three main effects at the 5% significance level.
Results
With either chemotherapeutic agent, tumor burden had hardly any effect on prognosis ( Table 1, A and B ) . Therefore, this factor can be disregarded in the final analysis and results of the experiment can be presented by survival estimates for the four groups defined by dose of chemotherapy and application of gt.
Treatment with topotecan
The survival data of mice treated with topotecan (n =79) either alone or in combination with gt are summarized in Table 1A and Figure 1A . The figure and the estimates from the corresponding Cox model demonstrate an interaction between the dose and concomitant application of gt. Survival rates were longest in mice receiving low -dose topotecan ( 6 mg /kg ) only. In mice treated with the higher dose of topotecan (12 mg /kg ), gt showed virtually no effect on survival time. Moreover, with this dose survival time was reduced compared to treatment with the lower dose. A small time-varying effect of the chemotherapy can be seen ( Fig 1A ) but this effect did not reach our defined significance level. In an additional sensitivity analysis we divided time into three intervals to account for the time varying effect of dose. This had hardly any influence on the estimated effect of gt.
Treatment with paclitaxel
In mice receiving paclitaxel at the lower dose ( 18 mg / kg) an initial substantial advantage in survival time is present ( Fig 1B ) . This advantage disappeared after a longer follow -up time. The model ( Table 1B ) demonstrates that high tumor burden increases the risks of dying slightly whereas gt reduces it slightly. Both effects are nonsignificant. The therapeutic efficacy of the higher dose of paclitaxel (36 mg /kg ) varies with time. Within the first 60 days of the study, a significant number of mice treated with the high dose of paclitaxel died. In the middle period, the risk is similar in the two dose groups, whereas the risk is slightly reduced in the full -dose group in the third period of follow -up. The P value for a time -varying effect of the dose of chemotherapy is significant at the 1% level. It is of note that gt might have a positive impact on survival in those mice who had received low-dose paclitaxel and belonged to the group of long -term survivors (>120 days ).
Discussion
Regardless of the chemotherapeutic agent tumor burden showed hardly any effects on the survival rates (Table 1 , A and B ). In the group treated with topotecan, survival rates were longest in mice receiving low -dose topotecan (6 mg / kg) alone ( Fig 1A, Table 1A ), the concomitant application of gt reduced survival rates significantly. It is difficult to find an explanation for the increased toxicity of this treatment approach because neither of both treatment modalities was seen to be associated with severe systemic toxicity. 5 It is also unclear, whether this effect is animal specific and /or due to the lack of the immune system in nude mice.
Topotecan and adv /rsv -tk gt, in combination with gcv, induce strand breaks in nascent DNA chains, thereby blocking protein biosynthesis and cell proliferation and finally causing cell death. 6 Topotecan can induce p53 -dependent and -independent apoptosis and can associate directly with double -and single-stranded DNA structures even in the absence of topoisomerase I. 7, 8 This is of note especially because Ov -ca-2774 cells are p53 mutated. Our animal study showed a dramatically reduced efficacy when adv/rsv -tk gt is applied in combination with the lower dose Figure 1 Survival rates for mice treated with chemotherapy alone or in combination with gt. A: Survival rates for mice treated with topotecan alone or in combination with gt. Survival rates were calculated for mice having low or high tumor burden at onset of treatment with topotecan ( either 6 or 12 mg / kg ) alone or in combination with gt. B: Survival rates of mice treated with paclitaxel alone or in combination with gt. Survival rates were calculated for mice having low or high tumor burden at onset of treatment with paclitaxel ( either 18 mg / kg or 36 mg / kg ) alone or in combination with gt.
of topotecan. This is not only in sharp contrast to our in vitro data, 1 but also in contrast to the results obtained with the human colorectal adenocarcinoma cell line HT-29 in vivo. 9 However, a direct comparison of our results with those reported by Wildner et al is difficult, as they inoculated tumors subcutaneously, whereas we used a model of intraperitoneal carcinomatosis. Moreover, they either used tumor cells stably transfected with hsv1 -tk or introduced the tk gene via an E1b -deleted replication competent adenovirus. It should be stressed that our vector is replication incompetent, e.g., the E1a and E1b genes are deleted. This is of special importance because expression of the E1A region of adv type 5 induces toposiomerase I. 10 Paclitaxel in combination with carboplatin or cisplatin is the therapeutic agent of choice in the first line chemotherapy of ovarian cancer after optimal tumor debulking surgery. Interestingly, gt had rather no effect on the survival of mice treated with either dose of paclitaxel ( Fig 1B and Table 1B ) . Moreover, a significant portion of animals receiving paclitaxel at 36 mg /kg either alone or in combination with gt died within the first 60 days.
In previous experiments with this animal model the lower dose levels of both chemotherapeutics were seen to be well tolerated and, more importantly, were not sufficient for long -term survival of mice bearing human ovarian cancer ( unpublished observation ). Survival rates of mice treated with the lower dosage of paclitaxel were longest and gt had no effect in this group ( Fig 1B ) . These data confirm the results of our in vitro experiments showing, that the efficacy of paclitaxel at any therapeutic concentration could not be enhanced significantly by simultaneous application of adv/ rsv -tk gt. 
